Forget Fortescue and buy these ASX shares

Let's see why the broker thinks investors should avoid the miner and buy these shares.

The team at Morgans has been busy updating its recommendations this week following a flurry of results releases.

Let's now take a look at two that it remains positive on and one that it thinks investors should be avoiding. Here's what it is recommending:

A happy male investor turns around on his chair to look at a friend while a laptop runs on his desk showing share price movements

Image source: Getty Images

Fortescue Ltd (ASX: FMG)

This iron ore giant may have delivered a "healthy" result in FY 2025, but that wasn't enough for Morgans to stop it from downgrading its shares.

The broker believes that its valuation is stretched and has downgraded its shares to a trim rating with a $19.00 price target. It said:

Healthy FY25 result, although dividend payout now constrained despite strong hematite margins. Iron Bridge contribution still modest and costly, with realisation risk persisting at 84%. Underlying EBITDA beat consensus +2%, while NPAT was -3%. At ~A$19/share, valuation stretched, leaving limited upside without either higher iron ore prices or a pivot in strategy. We downgrade to TRIM.

Nanosonics Ltd (ASX: NAN)

Morgans was pleased with the infection prevention company's FY 2025 results, highlighting that they were stronger than expected.

And with the Trophon business continuing to perform positively and showing signs of operating leverage, the broker sees lots of value on offer with its shares. As a result, it has retained its buy rating and $5.50 price target on them. It said:

FY25 result was a beat to expectations, supported by strong consumables growth and capital sales growth. Key short-term focus remains installed base growth which beat our pass-mark (>2k units), and early signs of upgrade cycle acceleration across the ageing fleet in North America.

Commentary around CORIS launch remains positive and potentially conservative, with phased commercial rollout expected now in FY27 followed by broader adoption in FY28. Timing hinges on FDA 510(k) approvals which we have seen recent evidence of backlog and delays to approvals. However, we view CORIS timing arbitrary over the life-cycle of the device and particularly so with the Trophon business humming along and showing strong operating leverage. No change to positive view or valuation. Target price of A$5.50 remains.

Tyro Payments Ltd (ASX: TYR)

Another ASX share that gets the seal of approval following its results release is payments company Tyro.

While its results were slightly softer than expected, it still believes it was a "solid" outcome. Particularly given its margin improvements.

As a result, the broker has retained its buy rating with an improved price target of $1.67. It said:

TYR's FY25 result was slightly below consensus expectations (-1%-2%) at revenue (A$486m) and EBITDA (A$61.5m), but more in line at NPAT (A$17.6m).  We saw this as a solid result overall, with continuing EBITDA margin improvement arguably the key positive highlight.

We lift our normalised PBT forecasts by +15%/+5% over the next two years, mainly on higher EBITDA margin assumptions. We note our EPS forecasts are +15%/-26% over the same timeframe, with our FY27 forecast impacted by TYR beginning to pay tax (which is slightly earlier than we thought). Our price target rises to A$1.67 (from A$1.55). With ~40% upside to our price target (A$1.67), we maintain a BUY rating.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended Nanosonics and Tyro Payments. The Motley Fool Australia has recommended Nanosonics and Tyro Payments. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Broker Notes

Happy wife holding her hands on her husband's shoulders while both look at a laptop.
Broker Notes

Top brokers name 3 ASX shares to buy next week

Brokers gave buy ratings to these ASX shares last week. Why are they bullish?

Read more »

a man wearing a hard hat and a high visibility vest stands with his arms crossed in front of heavy equipment at a mine site.
Broker Notes

BHP share price drops 13% to seven-month low in just 1 week. Do experts say buy?

Market analysts offer their advice as BHP shares plunge this week.

Read more »

A distressed young woman reads bad news on her smartphone while standing in a modern indoor setting.
Broker Notes

5 ASX 200 shares experts recommend we buy amid the market carnage this week

ASX 200 shares are down 5.2% this week and back in the red for 2026 overall.

Read more »

Comical investor reading documents and surrounded by calculators.
Broker Notes

Buy, hold, sell: Hub24, Reece, Ramsay Healthcare shares

Analysts reveal their ratings on this financial services provider, plumbing supplies company, and private hospital operator.

Read more »

A man with his back to the camera holds his hands to his head as he looks to a jagged red line trending sharply downward.
Broker Notes

Three of the worst performers in the ASX 200. Brokers think they're ready to bounce back

There could be a lot of value in these poor performers.

Read more »

Business man marking buy on board and underlining it.
Broker Notes

Leading brokers name 3 ASX shares to buy today

Brokers believe that now could be the time to buy these shares.

Read more »

Medical workers examine an x-ray or scan in a hospital laboratory.
Broker Notes

2 ASX shares tipped to grow up to 122% in the next 12 months

These companies could be on the cusp of something big.

Read more »

Thumbs down Facebook icon over dark screen.
Broker Notes

Why these 5 ASX shares were downgraded by brokers this week

Market analysts explain why they've downgraded these ASX stocks.

Read more »